GENETIC VARIABILITY OF PHARMACOKINETICS AND PHARMACODYNAMICS OF ANALGESICS (LAYERED MEDICINE)
Keywords:
analgesics, single nucleotide polymorphism, pharmacogenomicsAbstract
Pain therapy, the most widely spread disorder, tends more as other diseases, to administration of drug molecules targeted to the affected tissue at the right dose, or to the patient or patient groups (personalized medicine). A decisive determinant of this strategy is the genetic one, which is to some extent the basis of the variability of pharmacokinetic and pharmacodynamic response to analgesics in the patient population. The differences in action and response to analgesics are due in these cases to hyperfunctional or nonfunctional uni-nucleotide gene polymorphisms encoding enzyme-modified transport proteins or receptors involved in the biotransformation and dynamics of analgesics. Genomic testing increases therapeutic efficacy and avoids adverse effects especially in patients with long-term therapies.
References
Blakey JD, Hall IP. (2011): Current progress in pharmacogenetics, British Journal of Clinical Pharmacology, 71,6:824-831
Buchsbaum MS, Davis GC, Bunney VE Jr. (1977): Nature , London, 270: 620-622, pmid: 339 110 (CrossRef, PubMed, Google Scholar)
Ciskowski C, Madadi P, Phillips MS, Lawres AE, Koren G.(2009): Codeine, ultrarapid metabolism genotype and post-operative death, New England J.Med. 361(8):827-828
Coller JK, Barrat DT, Dahlen K, Loennechen MH. et al.(2006): ABCB1 genetic variability and metadone dosage requirements in opioid-dependent individuals, Clin.Pharmacol.Therap.80:682-690
Covic M.(2012): Farmacogenomica: o speranţă pentru medicina personalizată, Rev.Viaţa medicală, 16(1162)
Eijkelkamp N, Heijnen KJ, Elsenbruch S, Holtman G. Et al. (2009): G-protein coupled receptor kinase 6 control post-inflamatory visceral hyperalgesia, Brain Behav. Immun. 23:18-26
Fergusson SS, Barak LS, Zhang J, Caron MG. (1996): G-protein- coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins, Canadian Journ.Physiol.Pharm.,74:1095-1110
Fujita K, Ando Y, Yamamoto W, Miya T. et al. (2010): Association of UGTB2B7 and ABCB1 genotypes with morphine-induced adverse drug reaction in Japanese pacients with cancer, Cancer Chemotherapy Pharmacology. 65:251-258
Goins WF,Cohen JB, Glorioso JC.(2012): Gene therapy for the treatment of chronic peripheral nervous system pain , Neurobiology of Disease, 48:55-270
Goodman Gilman A, Rall TW, Nies As, Taylor P (1992): The pharmacological Basis of Therapeutics, vol.I, VIII Edition, Mc Graw-Hill International Edit, Medical Series, pg.3 și 33
Kibaly C, Loh HH, Law P-Y.(2010): A Mechanisms Approach to the Development of gene Therapy for Chronic Pain, International Review of Cell and Molecular Biology, vol.327, ISSN 1937-6448
Kirchheiner J, Niccken K, Bauer M, Wong M-L, Licinio J. et al.(2004)- Pharmacogenetics of antidepressants and antipsichotics: the contribution of the allelic variation to the phenotype af drug response , Mol.Psichiatry 9: 442-473
Kirchheiner J, Sasse J,Maineke I, Roots I et al.(2003): Trimipramine pharmacogenetics after intravenous and oral administration in carriers of CYP2D6 fenotypes predicting poor, exiensive and ultrahigh activity, Pharmacogenetics,13:721-728
Lotsch J, Geisslinger G, Tegeder I. (2009)-Genetic modulation of the pharmacological treatment of pain, Pharmacology and Therapeutics 124:168-184
Marker CL, Stoffel M, Wickman K. (2004): Spinal G-protein-gated K+ channels formed by GIRK1 and GIRK-2 subunits modulate thermal nociception and contribute to morphine analgesia, Journ.Neurosci.24, 2806-2812
Martin N, Boomsma D, Machin G (1997): A twin-pronged attack on complex traits, Nat.Genet., 17: 387-392 (CrossRef, Pubmed, Google Scholar)
Mercer S, CoopA.(2011): Opioid Analgesics and P-glycoprotein Eflux Transporters: Apotential Systems-LevelContribution to Analgesic Tolerance, Curr Top Med Chem, 11(9):1157-1164
Mogil JS (1999): The genetic mediation of individual differences in sensitivity to pain and its inhibition, Proc.Natl.Acad.Sci. USA, 96 (14) 7744-7751 (https://doi.org/10.1073/.pnas.96.14.7744)
Muralidharan A, Smith TM. (2011): Pain, analgesia and genetics, Journ.of Pharmacy and Pharmacology, 63:1387-1400
Nishizawa D, Fukuda K, Kasai S, Ogai Y, Hasegawa J et al.(2014): Association Between KCNJ6 (GIRK2) Gene Polymorphism rs 2835859 and Post-operative Analgesia, Pain sensitivity and Nicotin Dependence, Journal of Pharmacological Sciences, 126:253-263
Oertel BG, Kettner M, ScholichK, Renne C, Roskam B et al. (2009): A common human opioid receptor variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain, Journ.Biol.Chem. 284:6530-6535
Saland Lc, Chavez JB, Lee DC, Garcia RR, Caldwell KK. (2008): Chronic ethanol exposure increases the association of hippocampal mu-opioid receptors with G-protein –receptor kinase 2, Alcohol, 42: 493-497
Schiavone S, Neri M, Pomara C, Riezzo I. et al.(2017): Personalized medicine in the Paediatric Population: the Balance Between Pharmacogenethics Progress and Bioethics, Current Pharmaceutical Biotechnology, 18,3:253-262
Shabalina SA, Zaykin DV, Gris P, Ogurtsov AY et al. (2oo9): Expansion of the human mu-opioid receptor gene arhitecture: novel functional variants, Human Molecular Genetics, 18, 6:1037-1051
Smith SB, Marker CL, Perry C, Liao G. Et al. (2008): Quantitative trait locus and computational mapping identifies Kcnj9 (GIRK3) as a candidate gene affecting analgesia from multiple drug classes, Pharmacogenetics and Genomics, 18:231-241
Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S. et al.(2003): Impact of CYP2D6 genotype on postoperative tramadol analgesia, Pain, 105:232-238
Stamer UM, Stuber F (2007)-The pharmacogenetics of analgesia, Expert Opin.Pharmacotherapy, 8(14): 2235-2245
Stamer UM, Zhang L, Stuber F.(2010): Personalized therapy in pain management: where do stand?, Pharmacogenomics, 11(6):843-864
Tang C, Shou M, Rushmore TH, Mei Q et al. (2001): In vitro metabolism of celecoxib, a cyclooxygenase 2-inhibitor by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in vivo pharmacokinetics, Pharmacogenetics, 11: 223-235
Tyndale RF, Droll KP, Sellers EM (1997): Genetically deficient CYP2D6 metabolism provides protection against orale opiate dependence, Pharmacogenetics, 7(5):375-379
Wang GX, Zhang H, He FF, Fang XM. (2006): Effect of the CYP2D6*10 C188T polymorphism on postoperativ tramadol analgesia in a Chinese population, European Journal of Clinical Pharmacology.,62(11):927-931
Zhou SF.(2009): Polymorphism of human cyrochrome P450 2D6 and its clinical significance(Part II), Clinical Pharmacokinet.,48:761-804
CYP ALLELE Nomenclature Commitee (http://www.cypalleles .ki.se)
www.ncbi.nlm.nih.gov/SNP
Downloads
Published
How to Cite
Issue
Section
License
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. The journal allows readers to read, download, copy, distribute, print, search, link to the full texts or use the articles for any other lawful purpose.
The authors are the sole copyright owners of the published articles. The articles are distributed under the CC BY 4.0 license to the readers.
The readers are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.